Its effects on immune resilience, cardiovascular protection, cellular repair, neurological health, and metabolic stability make it a cornerstone therapy for clients seeking true regenerative optimization and extended healthspan
Eikon Therapeutics IPO $381.2M January 2026 Eikon Therapeutics priced an upsized IPO of 21,177,600 shares at $18.00 per share, generating expected gross proceeds of approximately $381 million before underwriting discounts, commissions, and expenses
The peptide's half-life of 2030 hours maintains elevated plasma concentrations across 48-hour intervals, making every-other-day dosing viable for extended cycles with slower receptor desensitization
Intracellular Penetration : The acetylated form demonstrates superior cellular uptake compared to standard glutathione, allowing higher concentrations of this master antioxidant to accumulate inside your cells where it supports healthy cellular function